This phase I trial is testing a new oral drug in patients with ER+, HER2- breast cancer.
This trial is treating patients with ER+, HER2- breast cancer.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Zeno Alpha Inc.
Eligible patients will receive oral ZN-c5 daily. To enrol in this trial, patients must be post menopausal.
Recruiting Hospitals Read More